Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

FORGOTTEN HISTORY: Abiomed s return on capital employed insights - The Untold Story

According to Benzinga Pro data Abiomed (NASDAQ:ABMD) posted a 19.67% decrease in earnings from Q2. Sales, however, increased by 5.25% over the previous quarter to $261.18 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Abiomed is not utilizing their capital as effectively as possible. Abiomed reached earnings of $56.95 million and sales of $248.14 million in Q2.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.